These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12137861)

  • 1. Relationship of baseline ovarian volume to ovarian response in World Health Organization II anovulatory patients who underwent ovulation induction with gonadotropins.
    Lass A; Vassiliev A; Decosterd G; Warne D; Loumaye E
    Fertil Steril; 2002 Aug; 78(2):265-9. PubMed ID: 12137861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of ovulation in World Health Organization group II anovulatory women undergoing follicular stimulation with recombinant human follicle-stimulating hormone: a comparison of recombinant human chorionic gonadotropin (rhCG) and urinary hCG.
    International Recombinant Human Chorionic Gonadotropin Study Group
    Fertil Steril; 2001 Jun; 75(6):1111-8. PubMed ID: 11384635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group.
    Coelingh Bennink HJ; Fauser BC; Out HJ
    Fertil Steril; 1998 Jan; 69(1):19-25. PubMed ID: 9457926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction.
    Serour GI; Aboulghar M; Al Bahar A; Hugues JN; Esmat K
    Reprod Biol Endocrinol; 2014 Jun; 12():52. PubMed ID: 24942155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial.
    Calaf Alsina J; Ruiz Balda JA; Romeu Sarrió A; Caballero Fernández V; Cano Trigo I; Gómez Parga JL; González Batres C; Rodríguez Escudero FJ
    BJOG; 2003 Dec; 110(12):1072-7. PubMed ID: 14664878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements.
    Homburg R; Howles CM
    Hum Reprod Update; 1999; 5(5):493-9. PubMed ID: 10582786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain.
    Burgués S;
    Hum Reprod; 2001 Dec; 16(12):2525-32. PubMed ID: 11726569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
    Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
    Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome.
    Weiss NS; Nahuis M; Bayram N; Mol BW; Van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2015 Sep; (9):CD010290. PubMed ID: 26350625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.
    Nugent D; Vandekerckhove P; Hughes E; Arnot M; Lilford R
    Cochrane Database Syst Rev; 2000; (4):CD000410. PubMed ID: 11034687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment.
    Yong PY; Brett S; Baird DT; Thong KJ
    Fertil Steril; 2003 Feb; 79(2):308-15. PubMed ID: 12568839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cumulative success of ovulation induction therapy with gonadotrophins in therapy-naïve anovulatory women: An observational study.
    Pontré J; Langdon F; Murray K; Livingston J; Hart R
    Aust N Z J Obstet Gynaecol; 2020 Apr; 60(2):271-277. PubMed ID: 31994179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.
    Lee KL; Couchman GM; Walmer DK
    J Assist Reprod Genet; 2005 Jan; 22(1):37-40. PubMed ID: 15807221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovulation induction and controlled ovarian stimulation using letrozole gonadotropin combination: A single center retrospective cohort study.
    Arya S; Kupesic-Plavsic S; Mulla ZD; Dwivedi AK; Crisp Z; Jose J; Noble LS
    Eur J Obstet Gynecol Reprod Biol; 2017 Nov; 218():123-128. PubMed ID: 28985546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.